施他宁、善得定和生长激素治疗重症急性胰腺炎的临床疗效研究

Clinical Study on Treatment of Severe Acute Pancreatitis With Somatostatin, Octreotide and Growth Hor- mone

目的:评价应用施他宁、善得定和生长激素治疗重症急性胰腺炎的疗效。方法:对1993年7月～2001年11月收治的21例应用施他宁、善得定和生长激素治疗的患者(观察组)进行回顾性分析,并与1991年10月～1995年3月收治的18例重症急性胰腺炎未用施他宁、善得定和生长激素治疗的患者(对照组)进行对照,观察两组治疗期间第1天、第3天、第7天APACHE(acutephysiology,and chronic health evaluation)Ⅱ评分的变化、住院日数、并发症、治愈率、死亡率、血淀粉酶恢复正常天数及主要症状的改善天数。结果:观察组能减少并发症,降低死亡率,缩短住院日数、血淀粉酶恢复天数及主要症状的改善天数。结论:施他宁、善得定和生长激素可能是较有效的治疗重症急性胰腺炎的药物。

OBJECTIVE:To evaluate the therapeutic effects of Somatostatin, Octreotide and growth hormone for severe acute pancreatitis(SAP) .METHODS:39 patients with SAP were divided into two groups.The treatment group including 21 patients admitted from July, 1993 to November, 2001 received traditional therapy in combination with Somatostatin, Octreotide or growth hormone; the control group including 18 patients admitted from October, 1991 to March, 1995 received only traditional therapy.The changes in the APACHE Ⅱon the first day, third day and seventh day after treatment, the duration of hospital stay, the incidence of complications, curative rate, mortality, the days for serum amylase restoration and the duration of improvement of main symptoms were compared between two groups.RESULTS: Somatostatin, Octreotide and growth hormone could reduce the occurence of complications, decrease the mortality and shorten the duration of hospital stay, days for serum amylase restoration and duration of improvement of main symptoms.CONCLUSION: It is suggested that Somatostatin, Octreotide and growth hormone may be the effective drugs for treating the patients with SAP.